Triazolam and temazepam are both benzodiazepine sleeping pills, but they occupy different niches because of one fundamental difference: triazolam acts fast and leaves the body quickly, while temazepam takes longer to kick in and lingers through the night. That distinction ripples through almost every practical question a person might have about these drugs, from which type of insomnia each one treats best to how likely you are to feel groggy the next morning or experience rebound sleep problems when you stop.
How They Work and Why Duration Matters
Both drugs enhance the activity of GABA, the brain’s main calming neurotransmitter. They bind to GABA-A receptors and act as positive allosteric modulators, meaning they amplify the effect of GABA that is already present rather than mimicking it directly. The result is sedation, muscle relaxation, reduced anxiety, and sleepiness.1PubMed Central. Different Benzodiazepines Bind with Distinct Binding Modes to GABA A Receptors Triazolam and temazepam both potentiate chloride ion flow through these receptors in a dose-dependent way.2European Journal of Pharmacology. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABAA receptor subtypes
Where they diverge is in how long they stick around. Triazolam has a half-life of roughly 1.5 to 5.5 hours, which makes it one of the shortest-acting benzodiazepines available. Temazepam’s half-life runs about 8 to 15 hours. In clinical terms, triazolam is classified as ultra-short-acting, while temazepam falls into the intermediate-acting category. This is the single most important difference between the two and drives most of the tradeoffs patients and prescribers weigh.
Falling Asleep Versus Staying Asleep
Because triazolam hits peak blood levels fast, it is primarily used for people who have trouble falling asleep at bedtime. You take it, you get drowsy within 15 to 30 minutes, and it does its job. But because it clears so quickly, it may not keep you asleep through the entire night. Some people on triazolam report waking in the early morning hours as the drug wears off, a phenomenon sometimes called early-morning insomnia that can paradoxically worsen sleep quality in the second half of the night.3PubMed. A reassessment of triazolam
Temazepam, by contrast, is a better fit for sleep-maintenance insomnia, the kind where you fall asleep adequately but wake repeatedly or too early. Its slower onset and longer presence in the bloodstream provide more sustained sedation across the night. The tradeoff is that temazepam may take 45 minutes to an hour to produce noticeable drowsiness, so timing the dose matters more. Most prescribing guidance suggests taking it 30 minutes before bed, but some people find they need to take it a bit earlier.
Memory and Next-Day Thinking
One of the starkest differences between these two drugs involves memory. Triazolam has a well-documented tendency to cause anterograde amnesia, meaning you may have trouble forming new memories for events that happen after you take it. In controlled studies comparing the two, triazolam produced consistent impairment of delayed recall, while temazepam did not cause significant memory problems at standard doses.4PubMed. Comparative amnestic effects of benzodiazepine hypnotic agents This is not a subtle laboratory finding. People on triazolam sometimes have complete blackouts for conversations or activities that occurred after dosing, which can be alarming and, in certain situations, dangerous.
When it comes to residual impairment the following day, the picture is more nuanced than you might expect. A study of healthy older adults with insomnia tested both drugs against placebo and found that at standard doses, neither triazolam nor temazepam caused meaningful next-day impairment on tests of attention, concentration, motor speed, or immediate memory. The one exception was a serial learning task, where both drugs at their higher doses produced some impairment.5International Psychogeriatrics. A Double-Blind Comparison of the Effects of Temazepam and Triazolam on Residual, Daytime Performance in Elderly Insomniacs The common assumption that short-acting drugs cause less hangover while long-acting ones leave you foggy is not reliably borne out at therapeutic doses. Temazepam does linger longer, but it is also less potent milligram-for-milligram, which can offset the expected daytime carryover.
Rebound Insomnia After Stopping
This is where triazolam’s short half-life creates real problems. When you stop taking a short-acting benzodiazepine after nightly use, the brain can struggle to readjust, and sleep often becomes temporarily worse than it was before you started the drug. A critical review of rebound insomnia found that disturbed sleep appeared after discontinuation of triazolam at the higher dose in seven of nine sleep-laboratory studies, and even at the lower dose in some cases. For temazepam, the risk of rebound insomnia was low.6PubMed. Rebound insomnia: a critical review
Rebound effects with triazolam are not limited to sleep. Withdrawal of the drug has been associated with both rebound insomnia and rebound anxiety, a worsening of anxious feelings that can feel intense and come on suddenly.7PubMed. Comparison of short and long half-life benzodiazepine hypnotics: triazolam and quazepam This pattern is consistent with what pharmacologists observe across the benzodiazepine class: shorter-acting agents tend to produce rebound symptoms that are more frequent and more intense, even though longer-acting agents carry their own withdrawal risks if used for extended periods. The practical upshot is that triazolam is best suited for very short-term or occasional use, while temazepam, though still habit-forming, is somewhat more forgiving if treatment extends beyond a few nights.
Drug Interactions and Metabolic Pathways
Triazolam and temazepam are processed by the liver through different pathways, and this matters a great deal when other medications are in the picture. Triazolam is primarily broken down by CYP3A4, a liver enzyme responsible for metabolizing a long list of common drugs. Anything that inhibits CYP3A4 can dramatically increase triazolam levels in the blood. Ketoconazole (an antifungal), certain HIV protease inhibitors, and some macrolide antibiotics like erythromycin all fall into this category. When triazolam levels climb unexpectedly, the result can be extreme oversedation.
Temazepam largely sidesteps this problem. It is metabolized mainly through direct conjugation (glucuronidation) rather than through the CYP3A4 pathway. A study testing whether erythromycin, a strong CYP3A4 inhibitor, altered temazepam’s behavior found no meaningful change in how the drug was absorbed, processed, or experienced. The researchers concluded that temazepam can be prescribed at usual doses in patients taking erythromycin, something that cannot be safely done with triazolam.8PubMed. Lack of interaction of erythromycin with temazepam This difference in metabolic pathways makes temazepam the safer choice when a patient is on multiple medications, a situation that becomes increasingly common with age.
Oral contraceptives offer another example. In women taking birth control pills containing estrogen, triazolam blood levels tended to increase (though not to a degree that reached statistical significance in one study), while temazepam levels actually decreased. The hormonal influence on each drug ran in opposite directions because of the different enzymes involved.9Nature / Clinical Pharmacology & Therapeutics. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics
Use in Older Adults
Age changes the equation significantly, especially for triazolam. Older adults clear triazolam from their bodies more slowly, resulting in higher blood levels from the same dose. A study published in the New England Journal of Medicine found that elderly subjects had higher plasma concentrations of triazolam than younger subjects given identical doses, due to reduced clearance. Sedation and impairment on cognitive tests were both greater in the older group.10PubMed. Sensitivity to triazolam in the elderly
The fall risk is a particular concern. Analysis of adverse-event databases in both Japan and the United States detected increased signals for falls and fractures in patients aged 70 and above who were taking triazolam.11PubMed Central. Appropriate use of triazolam in elderly patients considering a quantitative benefit-risk assessment based on the pharmacokinetic-pharmacodynamic modeling and simulation approach supported by real-world data A nighttime trip to the bathroom while triazolam is at peak effect can be genuinely dangerous. Temazepam is not risk-free in older adults either, and most guidelines urge caution with any benzodiazepine in this population. But temazepam’s lower potency and different metabolic pathway make dose-related surprises less likely. In practice, many geriatricians who still prescribe a benzodiazepine for an older patient tend to favor temazepam or a non-benzodiazepine alternative over triazolam.
Effects on Sleep Architecture
Sleep is not a uniform state. It cycles between lighter stages, deeper slow-wave sleep, and REM sleep, and drugs can alter how much time you spend in each phase. Temazepam, like other benzodiazepines, reduces slow-wave activity during the non-REM portions of sleep. A high-density EEG study in healthy young adults found that temazepam decreased both the amount and the amplitude of slow waves, with the effects varying depending on which part of the night and which brain region was measured.12PubMed Central. Effects of oral temazepam on slow waves during non-rapid eye movement sleep in healthy young adults: a high-density EEG investigation Slow-wave sleep is thought to be important for physical restoration and memory consolidation, so suppressing it is not a trivial side effect even if you feel like you slept well.
Triazolam similarly suppresses slow-wave sleep, but its rapid clearance means the suppression may be concentrated in the first half of the night. In theory, the second half of the night could see some recovery of deeper sleep stages, though the early-morning wakefulness that triazolam can trigger may offset that advantage. Neither drug leaves sleep architecture untouched, which is one reason clinicians generally prefer non-pharmacological approaches like cognitive behavioral therapy for insomnia when they are feasible.
Triazolam in Dental and Procedural Sedation
Triazolam has carved out an interesting role outside of nightly insomnia treatment. Dentists and oral surgeons commonly use it as an oral sedative for anxious patients undergoing procedures like implant placement or wisdom tooth extraction. Its rapid onset, relatively short duration, and amnesia-producing properties are actually advantages in this setting. A patient takes a low dose before the appointment, becomes relaxed and somewhat drowsy during the procedure, and often has little memory of it afterward. Studies have found triazolam at doses of 0.375 or 0.5 mg to be safe and highly effective at reducing anxious thoughts and disruptive movement during dental procedures compared with placebo.13PubMed Central. The efficacy and memory effects of oral triazolam premedication in highly anxious dental patients Typical doses in dental practice range from 0.125 to 0.25 mg, generally not exceeding 0.5 mg.14PubMed. Oral triazolam sedation in implant dentistry
Temazepam does not see much use in this role. Its slower onset means it does not reliably produce the rapid anxiolysis a dental office needs, and its longer duration means patients would be impaired well into the afternoon or evening. For procedural sedation, triazolam’s pharmacokinetic profile is genuinely better suited to the task.
An additional wrinkle for dental use: triazolam given under the tongue (sublingually) produces about 28% higher blood levels than the same dose swallowed, likely because the drug bypasses the liver’s first-pass metabolism. Peak concentrations are also higher by the sublingual route.15PubMed. Enhanced bioavailability of triazolam following sublingual versus oral administration Some dental practitioners use this sublingual approach to get a faster and more reliable sedation effect, but it also means the margin between an effective dose and an excessive one narrows.
Behavioral Effects and Abuse Potential
The question of whether triazolam is more “intoxicating” than temazepam has been tested directly in normal volunteers. In one set of experiments, triazolam at standard doses produced greater increases in ratings of drug strength, drunkenness, and sleepiness than temazepam at its standard doses. But the researchers suspected this comparison was misleading because the doses were not truly equivalent. When the temazepam dose was raised to 60 mg (double the usual top dose) and compared with triazolam 0.5 mg, the two produced comparable subjective effects. At that point temazepam actually caused more behavioral disruption than triazolam. The researchers concluded that across a wide dose range, triazolam was not more disruptive than temazepam and might even be less so.16PubMed. A comparison of the acute behavioral effects of triazolam and temazepam in normal volunteers
That said, triazolam’s rapid onset tends to produce a more noticeable “hit,” and drugs with fast onsets are generally considered to have higher abuse liability than slower-onset agents in the same class. This does not mean temazepam is without abuse potential. Both are Schedule IV controlled substances in the United States and carry warnings about dependence with prolonged use.
Prescribing Trends Around the World
Global prescribing patterns for these two drugs vary strikingly. Triazolam was banned in the United Kingdom in 1991 after regulators concluded that its psychiatric side effects, including amnesia, paradoxical agitation, and severe rebound insomnia, outweighed its benefits. The U.S. Food and Drug Administration kept triazolam on the market but required label changes and dose reductions. This transatlantic split became a case study in how different regulatory bodies can look at the same evidence and reach opposite conclusions.
Temazepam has remained widely available in most countries. In Australian general practice, for instance, temazepam was the single most commonly prescribed insomnia medication between 2011 and 2018, accounting for about a quarter of all insomnia drug prescriptions.17PubMed Central. Trends in the prescription of drugs used for insomnia: an open-cohort study in Australian general practice, 2011–2018 In many markets, both drugs have been increasingly displaced by newer non-benzodiazepine hypnotics (the “Z-drugs” like zolpidem and zopiclone) and by non-pharmacological treatments, but temazepam remains a staple where benzodiazepines are still prescribed for sleep.
Choosing Between Them
The choice between triazolam and temazepam usually comes down to the type of sleep problem and the patient’s overall medication and health profile. If the main issue is difficulty falling asleep in an otherwise healthy younger person who needs the drug for a few nights (jet lag, for example), triazolam’s fast onset and quick clearance can be appropriate. If the problem is waking through the night, temazepam’s longer duration is a better match. If the patient takes medications metabolized by CYP3A4, temazepam avoids a potentially dangerous drug interaction. And in older adults, temazepam is generally the less risky option, though the real question in that population is often whether a benzodiazepine is warranted at all.
Neither drug is meant for long-term nightly use. Guidelines from most sleep medicine organizations recommend benzodiazepine hypnotics for short courses only, and both triazolam and temazepam should be tapered rather than stopped abruptly after more than a few nights of consecutive use. The rebound risk is higher with triazolam, but temazepam withdrawal can also produce insomnia and anxiety if the drug has been used regularly for weeks.
When Tapering Becomes Necessary
If you have been taking either drug nightly for more than a couple of weeks, your prescriber will likely want to taper the dose gradually. The general principle for benzodiazepine withdrawal is that therapy should be stopped as early as possible, with a taper after moderate-dose or prolonged use. Short-acting agents like triazolam tend to produce rebound insomnia that is more frequent and more severe, while longer-acting agents can produce a more drawn-out but less intense withdrawal pattern. Some clinicians switch a patient from triazolam to a longer-acting benzodiazepine before tapering, precisely to smooth out the withdrawal curve. Others simply reduce the triazolam dose in small increments over several weeks. Either way, abrupt discontinuation of triazolam after regular nightly use is the approach most likely to produce a miserable few nights of sleep worse than whatever prompted the prescription in the first place.